Evaluating clinical effectiveness of 13-valent pneumococcal conjugate vaccination against pneumonia among middle-aged and older adults in Catalonia: results from the EPIVAC cohort study
Authors:
- Angel Vila-CorcolesAVAngel Vila-Corcoles
- Olga Ochoa-GondarOOOlga Ochoa-Gondar
- Cinta de DiegoCDCinta de Diego
- Eva SatueESEva Satue
- María AragónMAMaría Aragón
- Angel Vila-RoviraAVAngel Vila-Rovira
- Frederic Gomez-BertomeuFrederic Gomez-Bertomeu
- Ramon MagarolasRMRamon Magarolas
- Enric Figuerola-MassanaEFEnric Figuerola-Massana
- Xavier RagaXRXavier Raga
- Mar O. PerezMPMar O. Perez
- Frederic BallesterFBFrederic Ballester
Open Access
- 27 April 2018
- journal article
- research article
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 18 (1) , 1-10
Abstract
Benefits using the 13-valent pneumococcal conjugate vaccine (PCV13) in adults are controversial. This study investigated clinical effectiveness of PCV13 vaccination in preventing hospitalisation from pneumonia among middle-aged and older adults. Population-based cohort study involving 2,025,730 individuals ≥50 years in Catalonia, Spain, who were prospectively followed from 01/01/2015 to 31/12/2015. Primary outcomes were hospitalisation for pneumococcal or all-cause pneumonia and death from any cause. Cox regression models were used to evaluate the association between PCV13 vaccination and the risk of each outcome, adjusting for age, sex and major comorbidities/underlying risk conditions. Cohort members were observed for a total of 1,990,701 person-years, of which 6912 person-years were PCV13 vaccinated. Overall, crude incidence rates (per 100,000 person-years) were 82.8 (95% confidence interval [CI]: 77.7–88.1) for pneumococcal pneumonia, 637.9 (95% CI: 599.0–678.7) for all-cause pneumonia and 2367.2 (95% CI: 2222.8–2518.7) for all-cause death. After multivariable adjustments we found that the PCV13 vaccination did not alter significantly the risk of pneumococcal pneumonia (multivariable-adjusted hazard ratio [mHR]: 1.17; 95% CI: 0.75–1.83; p = 0.493) and all-cause death (mHR: 1.07; 95% CI: 0.97–1.18; p = 0.190), although it remained significantly associated with an increased risk of all-cause pneumonia (mHR: 1.69; 95% CI: 1.48–1.94; p < 0.001). In stratified analyses focused on middle-aged or elderly persons and immunocompromised or immunocompetent subjects, PCV13 vaccination did not appear effective either. Our data does not support clinical benefits of PCV13 vaccination against pneumonia among adults in Catalonia. It must be closely monitored in future studies involving more vaccinated person-time at-observation.Keywords
Funding Information
- Instituto de Salud Carlos III (PI15/01230)
This publication has 22 references indexed in Scilit:
- Pneumococcal Vaccination in High-Risk Individuals: Are We Doing It Right?Clinical and Vaccine Immunology, 2016
- Pneumococcal vaccinationCurrent Opinion in Infectious Diseases, 2016
- Efficacy of PPV23 in Preventing Pneumococcal Pneumonia in Adults at Increased Risk – A Systematic Review and Meta-AnalysisPLOS ONE, 2016
- Pneumococcal conjugate vaccine use in adultsExpert Review of Vaccines, 2015
- Cobertura de vacunación antineumocócica en niños con condiciones de riesgo en CataluñaEnfermedades Infecciosas y Microbiología Clínica, 2015
- Why the recent ACIP recommendations regarding conjugate pneumococcal vaccine in adults may be irrelevantHuman Vaccines & Immunotherapeutics, 2015
- Pneumococcal infection in adults: burden of diseaseClinical Microbiology and Infection, 2014
- Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccineVaccine, 2013
- Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adultsVaccine, 2013
- Vaccines for preventing pneumococcal infection in adultsCochrane Database of Systematic Reviews, 2013